

Prevalence of bla_{CTX M} Extended Spectrum Beta Lactamase Gene in Enterobacteriaceae from Critical Care Patients

R Indra Priyadharsini, A Kavitha, Reena Rajan, S Mathavi, K R Rajesh

Department of Microbiology, VMKV Medical College, Salem, Tamilnadu, India

Address for correspondence: Dr. Indra Priyadharsini, E-mail: priyabhasker@gmail.com

ABSTRACT

Context: Critical care units provide a favourable environment for the antimicrobial resistant organisms to disseminate. There is recent increase in number of extended spectrum beta lactamase (ESBL) producers because of the emergence of CTX M Beta lactamases produced by Enterobacteriaceae. They colonize the intestinal flora and spread with greater intensity in the community and hospital. Usage of Carbapenems becomes mandatory as the ESBL inhibitor combination antibiotics (Amoxicillin/Clavulanate) are not effective especially against CTX M ESBLs.

Aim: The aim of this study is to detect ESBL producing bla_{CTX M} gene in Enterobacteriaceae from infections in Critical care patients and to stress on the intensity of the problem and to make interventions to curb the emergence and dissemination of CTX M ESBLs.

Materials and Methods: A total of 118 Enterobacteriaceae isolates from Critical care unit patients were recovered from a variety of clinical specimens. Antimicrobial susceptibility test was done and isolates with resistance or with reduced susceptibility to any of the third generation Cephalosporins were selected for the study. Phenotypic confirmation of ESBL production was done by Double Disc Synergy Test and confirmed by minimum inhibitory concentration. Multiplex polymerase chain reaction was performed to screen the four groups of CTX-M ESBLs.

Results: Among the 118 isolates of Enterobacteriaceae 54 isolates were positive for CTX-M group I ESBL which constitutes 45.7 %.

Conclusions: Early detection of CTX M producing Enterobacteriaceae by continuous surveillance and thereby reducing their spread and restricted use of third generation Cephalosporins (3GC) antibiotics could be the possible routes to prevent the emergence and spread of CTX M ESBL producing organisms.

Keywords: CTX M, Critical care, Enterobacteriaceae, Extended spectrum beta lactamase

INTRODUCTION

Antimicrobial resistance is an emerging problem in treating the critically ill patients. The production of extended-spectrum beta-lactamase (ESBL) is one of the most important mechanisms of antimicrobial resistance. Recent increase in number of ESBLs attributes to the emergence of beta-lactamase producing bla_{CTX M} gene in Enterobacteriaceae.^[1] This study focuses on detecting bla_{CTX M} ESBL producing

Enterobacteriaceae from infections in critical care patients and to bring awareness to the clinicians about the intensity of the problem and to make interventions to curb the emergence and dissemination of CTX M ESBLs.

MATERIALS AND METHODS

A total of 118 Enterobacteriaceae from critical care units patients were recovered over a period of eight months (January 2010 to August 2010) from a variety of clinical specimens, i.e. urine, pus, sputum, blood, catheter tips, tracheal secretions, endotracheal tube etc. Identification of these isolates was done based on colony morphology on blood agar, MacConkey agar and by standard biochemical reactions.^[2] Antibiotic susceptibility testing was done on Muller-Hinton

Access this article online	
Quick Response Code: 	Website: www.jlponline.org
	DOI: 10.4103/0974-2727.86838

agar after standardizing the suspension to 0.5 McFarland's standards. The sensitivity of the isolates to 3 GC (Ceftriaxone, Ceftazidime and Cefotaxime) and to the other antibiotics such as Cotrimoxazole, Amikacin, Ciprofloxacin, Cefepime (Fourth generation cephalosporins), Augmentin and Imepenem was determined by Disc Diffusion Method. The results were interpreted as per Clinical and Laboratory Standards Institute (CLSI) recommendations.^[3] *Escherichia coli* ATCC 25922 strain was used for quality control. Isolates with resistance or with reduced Susceptibility to Ceftriaxone (< 21 mm), Ceftazidime (< 18 mm) and Cefotaxime (< 20 mm) were selected for the study.

Extended spectrum beta lactamase detection by double disc synergy test

In the DDST, synergy was determined between a disc consisting 20 mcg of Amoxicillin and 10 mcg of Clavulanic Acid (Augmentin) and 30 mcg disc of each of the 3 GC antibiotics placed at a distance of 30 mm apart on a lawn culture of the resistant isolate under test on Muller-Hinton Agar (MHA) (Hi Media, India).^[4] The test organism was considered to produce ESBL if the zone size around the test antibiotic increased towards the Augmentin disc. *Escherichia coli* ATCC 25922 and *Klebsiella pneumoniae* ATCC 700603 were used as negative and positive controls, respectively, for ESBL production.

Extended spectrum beta lactamase confirmation by minimum inhibitory concentration

MIC assay was performed on all strains that showed zone reduction for one or more of the 3GC antibiotics used in ESBL screening test. MIC was determined by agar dilution method against Ceftriaxone, Ceftazidime and Cefotaxime as described by National Committee for Clinical Laboratory Standards (NCCLS).^[5]

Polymerase chain reaction screening

Multiplex PCR was performed on 68 Enterobacteriaceae isolates which were positive for ESBL by phenotypic detection, to screen the four-groups of CTX-M type ESBLs as described by Pitout JDD et al., 2004.^[6] A loopful of bacteria grown in an agar plate were suspended in 50 µl of sterile water. Bacterial deoxyribonucleic acid (DNA) extraction was performed using the QIAMP DNA MINI kit (QIAGEN, Duesseeldorf, Germany). 1 µL of the DNA template was added to 20 µL of the PCR reaction mixture. The cycling conditions were: initial DNA release and denaturation at 94°C for 3 minutes, followed by 25 cycles of 94°C for 30 seconds, 57°C for 30 seconds and

72°C for 30 seconds, followed by final elongation step at 72° C for 5minutes. The PCR products were analyzed by gel electrophoresis with 2 % agarose in Tris/Borate/Ethylenediaminetetraacetic acid (TBE) with ethidium bromide (5 µg/ml) and visualized by ultraviolet (UV)-transillumination. A 100-bp DNA ladder (Invitrogen) was used as a marker.

RESULTS

A total of 118 Enterobacteriaceae isolates were obtained during the study period, of which 68 isolates showed enhanced zone size towards the Augmentin disc and were considered positive for ESBL by DDST. Of the 68 isolates, the zone around Cefotaxime was enhanced towards Augmentin in 51 isolates. Multiplex PCR yielded the products with predicted size for group 1 CTX-M (499 bp) enzyme in 54 isolates. The distribution of organisms in Enterobacteriaceae, results of their phenotypic confirmation for ESBL and PCR for CTX M were given in Table 1. MIC of 3GC antibiotics for ESBL producing Enterobacteriaceae is shown in Table 2. In our study among the 118 isolates of Enterobacteriaceae, 54 isolates were positive for CTX-M extended spectrum beta lactamase which constitutes 45.7% [Table 3] None of the isolates were Positive for CTX-M group II, CTX-M group III and CTX-M group IV ESBL's.

DISCUSSION

Many patients have to be hospitalized for a long duration and treated with heavy dose of antibiotics in the Critical Care units which facilitate them to acquire infection with multi drug resistant organisms.^[7-9] Furthermore, there is a remarkable rise in morbidity and mortality as well as the expenses for the patients in the critical care units.^[10,11] The commonest way of acquiring antibiotic resistance is by inactivating the antibiotic by the production of enzymes like beta-lactamases. The production of ESBLs is one of the most important mechanisms of antimicrobial resistance. Recent increase in number of ESBLs attributes to the emergence of CTX-M beta-lactamase producing Enterobacteriaceae.^[11] Many studies have been conducted in the Critical Care units regarding antimicrobial resistant organisms.^[11-14] But very few studies have been conducted about CTX M beta lactamases as bla_{CTXM} is newly emerged gene of ESBL having preference for Enterobacteriaceae.^[15,16] In our study, 68 isolates were found to be ESBL producers by phenotypic confirmation. Among them 35 isolates were *Escherichia coli*, 27 isolates were *Klebsiella* species. and 6 isolates were *Proteus* species. Among the 68

Table 1: Results of phenotypic confirmation of extended spectrum beta lactamase and CTX M polymerase chain reaction

Organism	Total numbers	Phenotypic confirmation	Group 1 CTX-M ESBL positive	CTX-M ESBL positive %
<i>Escherichia coli</i>	44	35	31	70.5%
<i>Klebsiella</i> species	54	27	23	42.5%
<i>Proteus</i> species	20	6	0	0 %

Phenotypic confirmation of ESBL is done by Double Disc Synergy Test. ESBL: Extended spectrum beta lactamase.

Multiplex PCR was performed to screen the four-groups of CTX-M type Extended spectrum beta lactamases. All the strains were positive only for group 1 CTX M ESBL.

Table 2: Minimum inhibitory concentration of 3gc antibiotics for *Escherichia coli* and *Klebsiella*

Cephotaxime (µg/ml)		Ceftriaxone (µg/ml)		Ceftazidime (µg/ml)	
<i>Escherichia coli</i>	<i>Klebsiella</i>	<i>Escherichia coli</i>	<i>Klebsiella</i>	<i>Escherichia coli</i>	<i>Klebsiella</i>
512	256	> 512	256	64	128

Table 3: Enterobacteriaceae positive for CTX M

CTX M positive	54
CTX M negative	64
Total no. of Enterobacteriaceae	118

ESBL producers, 54 isolates were positive for CTX-M group I ESBL and all the isolates were negative for other CTX M Groups (Group II, III and IV) confirmed by PCR. These data could indicate that the ESBL phenotype is due to production of ESBLs other than CTX-Ms. This also shows that CTX-M group I is the predominant form in Enterobacteriaceae.^[17] Our study is in accordance with James. S, *et al.* in which the most common CTX-M-type ESBL was CTX-M-15 in the critically ill patients recovered from blood and other sterile fluids.^[18] Macrorestriction polymorphism of genomic DNA determined by Pulse Field Gel Electrophoresis would indicate whether CTX M – 15 producing Enterobacteriaceae strains belong to a single clone.^[19] The major clones of *Escherichia coli* isolates with CTX M – 15 Beta lactamase had 78% similarity by PFGE and may share a common ancestor as stated by D.M. Livermore, P.M.Howkey, *et al.* CTX-M group I includes CTX- M-1, M-3, M-10 to M-12, M-15, M-22, M-23, M-28, M-29 and M-30.^[6] Among the 54 CTX-M group I ESBL producing Enterobacteriaceae, 31 isolates were *Escherichia coli*, 23 were *Klebsiella* species and none of the *Proteus* species produced CTX M ESBLs. *Escherichia coli* is the predominant CTX M group I ESBL producing Enterobacteriaceae in our study. Cefotaxime was considered to be the best 3GC antibiotic for phenotypic ESBL detection, as most of the isolates (75%) were positive in DDST for cefotaxime. CTX M beta lactamases has raised many concerns that, among the first 105 patients infected with CTX-M-15-producing *Escherichia coli* in Shropshire, there had been 28 deaths in 2002 as stated by D.M. Livermore P.M.Howkey, *et al.*^[1] The data of D.M.Livermore, Yuan M *et al.* is supportive of our study in which among the isolates with confirmed cephalosporin resistance, 51% were *Escherichia coli*, and a large number of *Escherichia coli* were with CTX-M enzymes.^[14]

The same study shows that CTX M lactamases are increasingly prevalent in Enterobacteriaceae.^[1] Endogenous intestinal flora formed by Enterobacteriaceae is the reservoir for CTX M beta lactamase infections and they colonize in the gut without harming the host. Munday CJ, *et al.*, and Valverde A *et al.*, have proved that CTX M ESBLs are carried by Enterobacteriaceae in the community fecal flora^[15,16] and they are predominantly responsible for urinary tract infections.^[20,21] This situation increases the potential of CTX M lactamases to disseminate rapidly in the community and produce serious infections which may not respond to the antibiotics that are used normally. D.M. Livermore, Yuan M, *et al.* has further mentioned that Enterobacteriaceae with CTX-M-15 (Group I) enzyme are resistant to inhibitor combinations (such as Piperacillin/Tazobactam and Amoxicillin/Clavulanate) by producing inhibitor-resistant penicillinases.^[14] Reconsideration of antibiotics becomes mandatory and higher level antibiotics like Carbapenems may have to be used which in turn escalates the cost and duration of hospital stay for the patients.

This condition is even worse in Critical care units because of factors such as severity of illness in these patients, closeness with other patients, many invasive procedures (catheter, endotracheal tube, IV lines etc) and failure to follow aseptic conditions (hand washing etc). All these create a fertile environment for the antimicrobial resistant bacteria to disseminate in the Critical Care units which insists special care to be exercised in the management of Critical Care patients. Early detection of CTX M producing Enterobacteriaceae by repeated surveillance and usage of 3GC antibiotics under proper guidance could be the possible routes to prevent the emergence and spread of CTX M ESBL producing organisms.

REFERENCES

1. Livermore DM, Hawkey PM. CTX M Changing The Face Of ESBLs in UK. J Antimicrob Chemother 2005;56:451-4.

2. Mackie, McCartney. Chapter 20 Enterobacteriaceae. J.Gerald Collee. Practical Medical Microbiology. 14th ed. New Delhi: Elsevier; 2007. p. 362-3.
3. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 20th informational supplement: M100-S20U Journal Of Clinical Microbiology 2010;30:1-16
4. Vercauteren E, Descheemaeker P, Ieven M, Sanders CG, Goossens H. Comparison of Screening methods for detection of extended spectrum lactamases and their prevalence among blood isolates of *Escherichia coli* and *Klebsiella* species in a Belgian Teaching Hospital. J Clin Microbiol 1997;35:2191-7.
5. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 5th ed. Wayne, PA, USA: NCCLS, Approved Standard; 2000. p. M7-A5.
6. Pitout JD, Hossain A, Hanson ND. Phenotypic and molecular detection of CTX-M lactamases produced by *Escherichia coli* and *Klebsiella* species J Clin Microbiol 2004;42:5715-21.
7. Haley RW, Bregman DA. The role of understaffing and overcrowding in recurrent outbreaks of staphylococcal infection in a neonatal special-care unit. J Infect Dis. 1982;145:875-85.
8. McGowan JE. Antibiotic resistance in hospital bacteria: current patterns, modes for appearance or spread, and economic impact. Rev Med Microbiol 1991;2:161-9.
9. Appelgren P, Hellstrom I, Weitzberg E, Soderlund V, Bindslev L, Ransjo U. Risk factors for nosocomial intensive care infection - a long-term prospective analysis. Acta Anaesthesiol Scand 2001;45:710-9.
10. Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm L, Redman R, *et al.* Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002;122:2115-21.
11. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, *et al.* The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995;274:639-44.
12. Hanberger H, Garcia-Rodriguez JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ, *et al.* Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. JAMA 1999;281:67-71.
13. Archibald L, Phillips L, Monnet D, McGowan JE, Tenover F, Gaynes R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997;24:211-5.
14. Livermore DM, Yuan M. Antibiotic resistance and production of extended-spectrum β -lactamases amongst *Klebsiella* spp from intensive care units in Europe. J Antimicrob Chemother 1996;38:409-24.
15. Munday CJ, Whitehead GM, Todd NJ, Campbell M, Hawkey PM. Predominance and genetic diversity of community- and hospital-acquired CTX-M extended-spectrum β -lactamases in York, UK. J Antimicrob Chemother 2004;54:628-33.
16. Valverde A, Coque TM, Sánchez-Moreno MP, Rollán A, Baquero F, Cantón R. Dramatic increase in prevalence of fecal carriage of extended-spectrum β -lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004;42:4769-75.
17. Baby Padmini S, Appala Raju B, Mani KR. Detection of Enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases from a tertiary care hospital in South India. Indian J Microbiol 2008;26:163-6.
18. Lewis JS 2nd, Herrera M, Wickes B, Patterson JE, Jorgensen JH. First report of the emergence of CTX-M-type extended-spectrum β -lactamases as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother 2007;51:4015-21.
19. Muzahed, Doi Y, Adams-Haduch JM, Shivannavar CT, Paterson DL, Gaddad SM. Faecal carriage of CTX-M-15-producing *Klebsiella pneumoniae* in patients with acute gastroenteritis. Indian J Med Res 2009;129:599-602.
20. Bonnet R, Growing Group of Extended-Spectrum β -Lactamases: the CTX-M Enzymes. Antimicrob Agents Chemother 2004;48:1-14.
21. Verma A, Desai N, Shannon K, Philpott-Howard J, Hill RL. Intra- and inter-generic plasmid-mediated spread of cephalosporin and aminoglycoside resistance amongst *Klebsiella aerogenes* K41 and other enterobacteria. Int J Antimicrob Agents 2001;17:123-9.

How to cite this article: Priyadharsini RI, Kavitha A, Rajan R, Mathavi S, Rajesh KR. Prevalence of bla CTX M extended spectrum beta lactamase gene in enterobacteriaceae from critical care patients. J Lab Physicians 2011;3:80-3.

Source of Support: Nil. **Conflict of Interest:** None declared.